Booming Clinical Trials Market in India

Product Code RCS00517
Publication Date August 2011
Publisher RNCOS
Product Type Report
Pages 145
ISBN Number not applicable
Change currency
PDF £630.00 €759 $996 BUY >
PRINT £760 €915 $1,202 BUY >
CDROM £760 €915 $1,202 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Booming Clinical Trials Market in India

India has billion plus population and a home for various life threatening diseases. These factors provide an opportunity for global medical practitioners and healthcare providers to consider India as an effective destination for research and clinical studies. India has registered fast growth in the number of clinical trials over the past few years, reflecting that the country has become one of the most attractive destinations for medical research.

According to our new research report, 'Booming Clinical Trials Market in India', the number of clinical studies by domestic and global players has sharply risen. The M&A activities, service agreements, and strategic collaboration have increased over the last four years. The majority of the deals in the contract research organizations market focused on establishing strategic alliances with other contract research organizations, technology providers, and pharmaceutical and biotech companies. In addition, on the back of favorable government support and effective regulatory mechanism provided by the ICMR and CDSCO, healthcare providers find it worthwhile to locate their trials in India. Besides, availability of skilled manpower and good medical infrastructure will augment the number of clinical trials from 1300 in 2009 to more than 1900 by 2013.

We have analyzed the Indian clinical trial market with emphasis on current market trends and future outlook. Our report has found that with the rising participation of private players and improvement in the number of medical professionals, new avenues of research will be developed in the country. All these factors will facilitate market development and boost market growth in future. A large number of patients for clinical trials are expected to strengthen the market even more.

Our study indicates that, India, over the last decade, has developed significant capabilities in clinical trials, along with certain capabilities in project management and data management. India is able to provide significant cost savings of 50-60% for clinical trials. With discovery research occupying close to one-third of the R&D expenditure for the western pharmaceutical industry, outsourcing to low-cost countries is logical. As the financial and regulatory pressure grows on the US and European pharmaceutical industry, it is expected to further propel the growth in the Indian clinical trial market.

Our report is an outcome of extensive research and prudent analysis of the Indian clinical trial market. The report covers all the necessary segments of the sector, providing reliable and latest data of the industry. The report also presents future outlook of different areas. Moreover, the description of key players and their recent activities have been covered in the report.

Contents

  • 1. Analyst View
  • 2. Research Methodology
  • 3. Clinical Trials Market Overview
    • 3.1 Clinical Trials Market
    • 3.2 Clinical Trials by Type
    • 3.3 Number of Clinical Trials
    • 3.4 State-wise Trials
  • 4. Growth Facilitators and Emerging Trends
    • 4.1 Cost Competitiveness in Conducting Clinical Trials
    • 4.2 Faster Completion of Clinical Trials
    • 4.3 Government Support
    • 4.4 Clinical Data Management: Demand of the Hour
    • 4.5 Pharma Outsourcing Market
    • 4.6 Pathology and Diagnostic Market
  • 5. Size and Patient Pool Availability
    • 5.1 Demographics Profile
    • 5.2 Disease Profile
    • 5.3 Patient Availability and Recruitment
  • 6. Infrastructure and Expertise
  • 7. Business Outsourcing Models Followed by Players
  • 8. Procedure for Conducting Clinical Trials
  • 9. Regulatory Environment
  • 10. Industry Bottlenecks and Precautions
  • 11. Cost Analysis for Clinical Trials
    • 11.1 Total Budget Cost
    • 11.2 Cost Comparison with US
    • 11.3 Cost Analysis by Phases
      • 11.3.1 Phase I (Cost of Utility and Staff)
      • 11.3.2 Phase II (Cost of Utility and Staff)
      • 11.3.3 Phase III (Cost of Utility and Staff)
      • 11.3.4 Phase IV (Cost of Utility and Staff)
  • 12. Competitive Landscape
    • 12.1 Overview
    • 12.2 Competitive Landscape
      • 12.2.1 Veeda Clinical Research
      • 12.2.2 SIRO Clinpharm Private Limited
      • 12.2.3 Sipra Labs Limited
      • 12.2.4 Clintrac International
      • 12.2.5 Clinigene International
      • 12.2.6 Quintiles India
      • 12.2.7 Synchron Research Services
      • 12.2.8 Max Neeman International
      • 12.2.9 DiagnoSearch Life Sciences
      • 12.2.10 Vimta Labs
      • 12.2.11 Lambda Therapeutic Research
      • 12.2.12 Ecron Acunova
  • List of Figures:
    • Figure 3-1: Clinical Research Outsourcing Market (Million US$), 2009-2015
    • Figure 3-2: Clinical Trials by Phase (%)
    • Figure 3-3: Clinical Trials by Therapy (%)
    • Figure 3-4: Clinical Trials by Funding (%)
    • Figure 3-5: Number of Global and Local Trials Permitted (2007-2010)
    • Figure 3-6: Number of Clinical Trials (2007 & 2009)
    • Figure 4-1: Average Annual Cost for Conducting Clinical Trials in Comparison to US
    • Figure 4-2: Investigator Cost per Visit in Comparison to US, UK and Singapore
    • Figure 4-3: Numbers of Clinical Trials Completed on Time in Comparison to UK, US and Germany
    • Figure 4-4: Time Taken for Conducting Clinical Trials by Phase in Comparison to US (Months)
    • Figure 4-5: Pharma Outsourcing Market (Billion US$), 2009-2013
    • Figure 4-6: Pharma Outsourcing Market by Segment (%), 2008
    • Figure 4-7: IVD Market (Million US$), 2009 & 2012
    • Figure 5-1: Population (Million), 2009-2013
    • Figure 5-2: Population Breakup by Age Group (%), 2009-2013
    • Figure 5-3: New and Total Number of Cancer Patients ('000)
    • Figure 5-4: Number of Hypertension Patients (Million), 2009 & 2025
    • Figure 5-5: Number of Coronary Heart Disease Patients (Million), 2010 & 2015
    • Figure 5-6: Recruitment Time for Patients Participating in Clinical Trials in Comparison to US (Days)
    • Figure 5-7: Number of Patient per Site in Comparison to US
    • Figure 6-1: Annual Supply of Science Graduates and Postgraduates ('000)
    • Figure 6-2: Number of Graduates and Postgraduates (Million), 2004
    • Figure 6-3: Share of Science Doctorates in Total Doctorates (2004)
    • Figure 6-4: Number of Doctors in Comparison to US and Germany (per '000 Population), 2009
    • Figure 6-5: Demand-Supply Gap in Clinical Research Professionals (Number), 2010
    • Figure 6-6: Number of GCP Trained Investigators (2002 & 2005)
    • Figure 6-7: Number of GCP Trained Investigators in Comparison to US
    • Figure 6-8: Number of Hospital Beds ('000), 2009-2013
    • Figure 6-9: Hospital Beds Density of Key Countries (per '000 Population), 2010
    • Figure 6-10: Number of Industry Sponsored Phase II-III Clinical Trial Sites of Key Countries
    • Figure 11-1: Average Cost per Patient for Conducting Clinical Trials in Comparison to UK, US and Germany (US$)
    • Figure 11-2: Average Cost per Patient for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
    • Figure 11-3: Average Cost per Patient for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
    • Figure 11-4: Annual Cost of Office Space for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
    • Figure 11-5: Average Cost per Patient for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
    • Figure 11-6: Annual Cost of Office Space for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
    • Figure 11-7: Average Cost per Patient for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
    • Figure 11-8: Annual Cost of Office Space for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
  • List of Tables:
    • Table 3-1: Details of State-wise Clinical Trials (January-July 2011)
    • Table 4-1: Features of Clinical Trials in Comparison to US
    • Table 5-1: Number of Deaths due to Leading Causes in Middle Income Countries (Million)
    • Table 5-2: Number of Diabetic Patients in Age Group 20-79 ('000), 2010
    • Table 5-3: Forecast for Number of Diabetic Patients in Age Group 20-79 ('000), 2030
    • Table 5-4: New Cancers Incidences (per '00,000 Females), 2005
    • Table 5-5: New Cancers Incidences (per '00,000 Males), 2005
    • Table 5-6: Obesity Statistics (2009)
    • Table 6-1: Structure of Medical Education
    • Table 6-2: Number of GLA Approved Facilities by Type
    • Table 9-1: Regulatory Bodies Involved in Pharmaceutical Regulation
    • Table 9-2: Regulatory Timelines for Conducting Clinical Trials
    • Table 11-1: Average Cost of Clinical Research in Comparison to US by Phase (Million US$)
    • Table 11-2: Calculation of Clinical Trials Costs Savings in Comparison to US
    • Table 11-3: Annual Cost of Staff for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
    • Table 11-4: Annual Cost of Utility for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
    • Table 11-5: Annual Cost of Staff for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
    • Table 11-6: Annual Cost of Utility for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
    • Table 11-7: Annual Cost of Staff for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
    • Table 11-8: Annual Cost of Utility for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
    • Table 11-9: Annual Cost of Staff for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
    • Table 11-10: Annual Cost of Utility for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)